MedTrace Logo

Effectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment

NCT07585045 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2026-05-13

No results posted yet for this study

Summary

Fibromyalgia is a complex widespread pain disorder. OBJECTIVES To evaluate the effectiveness of oral magnesium supplementation in reducing symptom severity among fibromyalgia patients who have not responded to standard treatment, using validated scoring systems such as the Fibromyalgia Impact Questionnaire Revised (FIQR).

Conditions

  • Fibromyalgia

Interventions

DIETARY_SUPPLEMENT

Magnesium glycinate

Fibromyalgia patients who have shown no improvement after at least two months of single standard therapy (amitriptyline, duloxetine, pregabalin) will be recruited from rheumatology clinics. Half participant randomly will be assigned to receive oral magnesium glycinate 850 mg once daily at night for 24 weeks.

DIETARY_SUPPLEMENT

Vitamins

Fibromyalgia patients who have shown no improvement after at least two months of single standard therapy (amitriptyline, duloxetine, pregabalin) will be recruited from rheumatology clinics. Half participant will be randomly assigned to receive oral placebo (vitamin supplement) daily for 24 weeks.

Sponsors & Collaborators

  • Shaikh Zayed Hospital, Lahore

    lead OTHER

Principal Investigators

  • Masooma Hashmat, FCPS · Shaikh Zayed Hospital, Lahore

  • Ayesha Humayun, FCPS, PhD · Shaikh Zayed Hospital, Lahore

  • Aflak Rasheed, FCPS · Shaikh Zayed Hospital, Lahore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-16
Primary Completion
2026-12-31
Completion
2027-02-26

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07585045 on ClinicalTrials.gov